AVTE Nov 2024 2.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:43PM EDT
| Previous close | 0.4000 |
| Open | 0.4500 |
| Bid | 0.3000 |
| Ask | 0.4500 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3000 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 718 |
ZacksAerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Barrons.comAerovate Therapeutics Stock Dropped Over 90%. Here’s Why.
The company said its blood pressure drug failed in Phase 2 testing. The drug is its sole asset, according to Jefferies analysts.
Investor's Business DailyWhy 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%.
© 2024 Yahoo. All rights reserved.